Phoenix pharma firm gets FDA nod on cannabis treatment; sends stock soaring

Phoenix-based Insys Therapeutics Inc. (Nasdaq: INSYS) has received approval from the U.S. Food and Drug Administration to begin marketing its cannabis treatment. The company's product, Syndros, is an orally administered liquid formula of the pharmaceutical cannabinoid dronabinol, which is a pharmaceutical version of THC, or tetrahydrocannabinol. The FDA is allowing Insys to treat anorexia associated with weight loss in patients with AIDS as well as nausea and vomiting associated with cancer chemotherapy…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news